The transaction was signed and completed on 1 January 2026. Under the agreement, Auro Pharma has acquired the branded non-oncology prescription formulations business of Khandelwal Laboratories as a going concern on a slump-sale basis. The acquisition includes inventory, intellectual property, employees, contracts, and other associated assets. The total cash consideration for the transaction is Rs 325 crore.
The acquisition is expected to strengthen the company’s pain management and anti-infective portfolio, complementing its existing offerings and supporting expansion in the domestic market.
Aurobindo Pharma is principally engaged in the manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals, and related services.
The company’s consolidated net profit increased 3.8% to Rs 848.45 crore on 7.7% increase in net sales to Rs 8,236.96 crore in Q2 FY26 over Q2 FY25.
"Prevent unauthorised transactions in your account ; Update your mobile numbers/email IDs with Us. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day” - Issued in the interest of Investors"
"KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary."
"No need to issue cheques by investors while subscribing to Equity IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."